Viral Decay Rates are Similar in HIV-infected Patients with and without TB Coinfection during Treatment with an Efavirenz-based Regimen

Viral decay rates during efavirenz-based therapy were compared between HIV-infected patients without (N=40) and with tuberculosis coinfection on concurrent antituberculous therapy (N=34). Phase 1 and II viral decay rates were similar in the two groups (P>0.05). Overall, concurrent antituberculous therapy did not reduce the efficacy of the HIV treatment